0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Effects of Long-Term Postoperative Interferon-α Therapy on Intrahepatic Recurrence after Resection of Hepatitis C Virus–Related Hepatocellular Carcinoma: A Randomized, Controlled Trial

Shoji Kubo, MD; Shuhei Nishiguchi, MD; Kazuhiro Hirohashi, MD; Hiromu Tanaka, MD; Taichi Shuto, MD; Osamu Yamazaki, MD; Susumu Shiomi, MD; Akihiro Tamori, MD; Hiroko Oka, MD; Sumito Igawa, MD; Tetsuo Kuroki, MD; and Hiroaki Kinoshita, MD
[+] Article and Author Information

From Osaka City University Medical School, Osaka City General Hospital, and Joto Central Hospital, Osaka, Japan.


†Deceased.

Acknowledgments: The authors thank Daniel K. Podolsky, MD, of Massachusetts General Hospital, Harvard Medical School, for critical reading of the manuscript and Hiroyuki Yasuda for statistical analysis.

Grant Support: In part by grants from the Ministry of Education, Science, Sports, and Culture (09671330) and the Ministry of Health and Welfare, Japan.

Requests for Single Reprints: Shuhei Nishiguchi, MD, Third Department of Internal Medicine, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan; e-mail, snishiguch@med.osaka-cu.ac.jp.

Current Author Addresses: Drs. Kubo, Hirohashi, Tanaka, Shuto, and Kinoshita: Second Department of Surgery, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.

Drs. Nishiguchi, Shiomi, and Tamori: Third Department of Internal Medicine, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno-ku, Osaka 545 8585, Japan.

Dr. Yamazaki: Department of General and Gastrointestinal Surgery, Osaka City General Hospital, 2-13-22 Miyakojimahondori, Miyakojima-ku, Osaka 534-0021, Japan.

Dr. Oka: Department of Gastroenterology, Osaka City General Hospital, 2-13-22 Miyakojimahondori, Miyakojima-ku, Osaka 534-0021, Japan.

Dr. Igawa: Joto Central Hospital, 5-13-47 Shiginonishi, Joto-ku, Osaka 536-0014, Japan.

Author Contributions: Conception and design: S. Kubo, S. Nishiguchi, T. Kuroki, H. Kinoshita.

Analysis and interpretation of the data: S. Kubo, T. Kuroki, S. Nishiguchi.

Drafting of the article: S. Kubo.

Critical revision of the article for important intellectual content: S. Nishiguchi.

Final approval of the article: S. Kubo, S. Nishiguchi, K. Hirohashi, H. Tanaka, T. Shuto, O. Yamazaki, S. Shiomi, A. Tamori, H. Oka, S. Igawa, H. Kinoshita.

Provision of study materials or patients: S. Kubo, S. Nishiguchi, K. Hirohashi, H. Tanaka, T. Shuto, O. Yamazaki, S. Shiomi, A. Tamori, H. Oka, S. Igawa, T. Kuroki, H. Kinoshita.

Statistical expertise: S. Kubo, S. Nishiguchi.

Obtaining of funding: S. Kubo, H. Kinoshita.

Administrative, technical, or logistic support: S. Kubo, S. Nishiguchi, K. Hirohashi, H. Tanaka, T. Shuto, O. Yamazaki, S. Shiomi, A. Tamori, H. Oka, S. Igawa, T. Kuroki.

Collection and assembly of data: S. Kubo, S. Nishiguchi, K. Hirohashi, H. Tanaka, O. Yamazaki, S. Shiomi, A. Tamori, H. Oka, S. Igawa.


Ann Intern Med. 2001;134(10):963-967. doi:10.7326/0003-4819-134-10-200105150-00010
Text Size: A A A

Background: Interferon therapy decreases the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.

Objective: To evaluate effects of interferon-α on recurrence after resection of hepatitis C virus–related hepatocellular carcinoma.

Design: Randomized, controlled trial.

Setting: University hospital, medical center, and affiliated hospital in Osaka, Japan.

Patients: 30 men were randomly allocated after resection to the interferon-α group (n = 15) or the control group (n = 15).

Intervention: Patients in the interferon-α group received interferon-α, 6 MIU intramuscularly daily for 2 weeks, then three times weekly for 14 weeks, and finally twice weekly for 88 weeks.

Measurements: Recurrence rates after resection.

Results: Recurrent tumors were detected in 5 patients in the interferon-α group and in 12 control patients. The recurrence rate was significantly lower in the interferon-α group than in the control group (P = 0.037).

Conclusion: Postoperative interferon-α therapy appears to decrease recurrence after resection of hepatitis C virus–related hepatocellular carcinoma.

Figures

Grahic Jump Location
Figure.
Recurrence rates in the interferon-α (solid line) and control (dotted line) groups.P

Tick marks show censoring times. All censored patients were alive without recurrence of hepatocellular carcinoma at the end of this trial. The recurrence rate was significantly lower in the interferon-α group than in the control group according to the log-rank test (  = 0.037).

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Does Interferon-α Prevent Recurrence of Malignant Tumors in Patients with Hepatitis C–Related Liver Cancer?

The summary below is from the full report titled “Effects of Long-Term Postoperative Interferon-α Therapy on Intrahepatic Recurrence after Resection of Hepatitis C Virus–Related Hepatocellular Carcinoma. A Randomized, Controlled Trial.” It is in the 15 May 2001 issue of Annals of Internal Medicine (volume 134, pages 963-967). The authors are S Kubo, S Nishiguchi, K Hirohashi, H Tanaka, T Shuto, O Yamazaki, S Shiomi, A Tamori, H Oka, S Igawa, T Kuroki, and H Kinoshita.

Read More...

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)